Brief: XBiotech Announces Upcoming Phase 2 Clinical Studies In Dermatology
16/04/2018 13:18
April 16 (Reuters) - XBiotech Inc XBIT.O :
* XBIOTECH ANNOUNCES UPCOMING PHASE 2 CLINICAL STUDIES IN
DERMATOLOGY
* XBIOTECH INC - CO WOULD EVALUATE A NEW SUBCUTANEOUS
FORMULATION
OF CO'S TRUE HUMAN MONOCLONAL ANTIBODY, MABP1, IN TWO SEPARATE
PHASE 2 STUDIES
* XBIOTECH INC - UPCOMING PHASE 2 CLINICAL STUDIES IN
PATIENTS
WITH MODERATE TO SEVERE ATOPIC DERMATITIS (AD) AND HIDRADENITIS
SUPPURATIVA (HS)
Source text for Eikon: ID:nGNX1HZZj5
Further company coverage: XBIT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on XBiotech
See all newsBrief: XBiotech Announces Positive Final Efficacy Results From Phase II Taskin Trial
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: XBiotech Inc - John Simard To Retire As CEO Of XBiotech - SEC Filing
Brief: Xbiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke